GleamWall
中文EN

CBDY Target Group Inc.

Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1586554 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY0.1%
TTM net income YoY-155.4%
TTM EPS YoY-150.0%
Revenue 3-yr CAGR40.5%
Net income 3-yr CAGR—

Margins

Gross margin42.0%
Operating margin—
Net margin-30.2%
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-24.6%
ROIC (approx.)—
Asset turnover0.82x

Leverage & solvency

Liabilities / assets245.5%
Debt / equity—
Current ratio0.20x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.18x
Accruals ratio-20.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$2.01M$1.38M$879,442$735,190$499,650$1.25M$1.40M$1.86M
Cost of revenue$1.02M$752,520$687,655$447,991$235,291$500,303$629,612$777,447
Gross profit$994,062$628,318$191,787$287,199$264,359$745,421$770,827$1.08M
Interest expense$288,740$289,170$288,249$262,767$266,716$263,970$250,766$263,002
Pretax income-$168,281-$239,812-$550,356-$552,307-$479,392-$219,770-$108,213$215,958
Net income-$168,281-$239,812-$550,356-$552,307-$479,392-$219,770-$108,213$215,958
EPS (basic)-0.00-0.00-0.00—-0.00-0.00-0.00—
EPS (diluted)-0.00-0.00-0.00—-0.00-0.00-0.00—
Weighted avg. shares (diluted)617.03M617.03M617.03M—617.03M617.03M617.03M—
Banking
Loans, net—————$73,300——
Balance sheet
Cash & equivalents$189,235$14,006$209,897$108,800$345,748$845,927$781,703$1.88M
Receivables$1.12M$522,374$454,765$446,283$312,541$311,894$645,564$77,092
Inventory$1.46M$1.72M$1.68M$1.67M$1.42M$1.67M$1.67M$882,279
Current assets$2.91M$2.37M$2.48M$2.33M$2.18M$2.31M$2.41M$3.10M
PP&E, net$2.89M$3.03M$3.31M$3.55M$3.73M$3.98M$3.97M$4.19M
Goodwill$251,178$250,786$255,668$260,016$255,989$261,228$247,899$247,685
Total assets$6.07M$5.68M$6.08M$6.18M$6.20M$6.59M$6.67M$7.57M
Current liabilities$14.22M$13.60M$13.82M$13.38M$12.74M$9.97M$12.34M$13.10M
Short-term debt$7.35M$7.33M$7.48M$7.60M$7.49M$7.64M$7.25M$7.24M
Long-term debt$7.35M$7.33M$7.48M$7.60M$7.49M$7.64M$7.25M$7.24M
Total debt$14.69M$14.67M$14.95M$15.21M$14.97M$15.28M$14.50M$14.49M
Total liabilities$14.90M$14.33M$14.62M$14.24M$13.63M$13.62M$13.29M$14.08M
Shareholders' equity-$8.83M-$8.66M-$8.54M-$8.06M-$7.43M-$7.03M-$6.62M-$6.51M
Net debt$14.50M$14.65M$14.74M$15.10M$14.63M$14.43M$13.72M$12.61M
Shares outstanding617.03M617.03M617.03M617.03M617.03M617.03M617.03M617.03M
Cash flow statement
Operating cash flow$293,612-$222,908-$93,665-$250,788-$506,066$484,434-$570,005$736,437
Investing cash flow-$80,312-$6,516-$40,055$13,022$24,488$15,904$27,965-$50,094
Financing cash flow-$33,226$30,938$240,570-$682-$8,135-$498,557-$557,440$4,942
Depreciation & amortization$227,580$228,960$229,653$225,338$227,647$226,942$218,476$269,923

Free plan shows the latest 8 periods; Pro shows all 52 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.